- Sanofi invested EUR 30 million in the new cell culture plant.
- The plant began operations in June 2011 at Industriepark Höchst.
- It will produce monoclonal antibodies for preclinical and clinical trials.
- The facility doubles the site's cell culture production capacity.
Investment and Operations
Sanofi commissioned a new cell culture plant at Industriepark Höchst in June 2011, investing around EUR 30 million. The facility will produce monoclonal antibodies using biotechnological processes, aimed at preclinical and clinical trials.
Production Capacity
The new plant more than doubles the cell culture production capacity at the site. This expansion aligns with Sanofi's increasing focus on targeted biopharmaceutical therapies, a rapidly growing market globally.
Monoclonal Antibodies
Monoclonal antibodies are specialized protein molecules that can inhibit disease or enhance the body's natural defenses. They are used in treatments for cancer, diabetes, autoimmune diseases, and infections.
Workforce
Around 80 employees will work at the new cell culture plant, contributing to the production of these therapeutic antibodies.
